Is 'off-protocol' chemotherapy for androgen-independent carcinoma of prostate warranted?

S. Mani, N. J. Vogelzang

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

It is acceptable to treat HRPC patients with off-protocol chemotherapy if these patients do not accept protocol therapy or are ineligible for such therapy. The choice of cytotoxic agent needs to be individually assessed, depending on range of tolerable toxicities and personal preferences of the physician and patient. At the present time, single-agent therapy with oral or intravenous cyclophosphamide or mitoxantrone/prednisone may offer optimal palliation without undue side effects in a predictable number of patients.

Original languageEnglish (US)
Pages (from-to)749-768
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume10
Issue number3
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this